The Mechanism of Action of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction

Journal of the Association of Physicians of India 2026

View at publisher
Authors: RR Mantri, Agam Vora, Asif Hasan, Abhishek Raval, RS Kumar, Sachin K Gupta, Subhamoy Chatterjee, Srinivas SV, Kailash Chandra, Krishnamoorthy S, KHIZER HUSSAIN JUNAIDY, Febin Francis
+2 more Amarnath Sugumaran, Senthilnathan Mohanasundaram
DOI: 10.59556/japi.74.1294
Cited by: 0
References: 38

Abstract

Mineralocorticoid receptor antagonists (MRAs) are one of the guideline-directed medical therapies for patients with heart failure and chronic kidney disease due to their anti-inflammatory and antifibrotic effects. MRAs regulate mineralocorticoid receptor (MR) signaling by inhibiting aldosterone binding to MR. MRAs are classified into steroidal and nonsteroidal categories based on their molecular interactions and clinical applications. Steroidal MRAs have been widely used in clinical practice and have demonstrated significant efficacy. Continuous advancements in the field have led to the development of nonsteroidal MRAs with greater receptor selectivity and better safety profile.

Fields of Study & Subjects

Hormonal Regulation and Hypertension Heart Failure Treatment and Management Cardiac Fibrosis and Remodeling

Publication details

Journal / source
Journal of the Association of Physicians of India
Volume
74
Issue
1
Pages
15–18
Publication date
1 January 2026
Language
EN